Review article: Drugs interfering with visceral sensitivity for the treatment of functional gastrointestinal disorders - The clinical evidence

Alimentary Pharmacology and Therapeutics

Volumn 21, Issue 6, 2005, Pages 633-651

  Kuiken, S D ^a   Tytgat, G N ^a   Boeckxstaens, G E ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; ALOSETRON; ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BUSPIRONE; CILANSETRON; DELTA OPIATE RECEPTOR AGONIST; FEDOTOZINE; FENTANYL; FLUOXETINE; IMIPRAMINE; KAPPA OPIATE RECEPTOR AGONIST; LOPERAMIDE; MU OPIATE RECEPTOR AGONIST; ONDANSETRON; OPIATE AGONIST; PAROXETINE; PLACEBO; PRUCALOPRIDE; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR; SOMATOSTATIN DERIVATIVE; SUMATRIPTAN; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMEBUTINE; TROPISETRON; UNINDEXED DRUG; VENLAFAXINE;

ABDOMINAL PAIN; ANALGESIC ACTIVITY; ANTINOCICEPTION; CLINICAL TRIAL; CONSTIPATION; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG EFFICACY; DRUG SENSITIVITY; DYSPEPSIA; HUMAN; INTESTINE CONTRACTION; IRRITABLE COLON; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; VISCERAL PAIN;

ABDOMINAL PAIN; ADRENERGIC ALPHA-ANTAGONISTS; ANTIDEPRESSIVE AGENTS; GASTROINTESTINAL DISEASES; HUMANS; HYPERSENSITIVITY; NARCOTICS; SEROTONIN AGENTS; SOMATOSTATIN; VISCERA;

EID: 16344363993     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2005.02392.x     Document Type: Review

References (135)

1. Thompson WG, Longstreth GF, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. Gut 1999; 45 (Suppl. 2): II43-7.
2. Mayer EA, Gebhart GF. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 1994; 107: 271-93.
3. Cervero F, Laird JM. Visceral pain. Lancet 1999; 353: 2145-8.
4. Whitehead WE, Delvaux M. Standardization of barostat procedures for testing smooth muscle tone and sensory thresholds in the gastrointestinal tract. The Working Team of Glaxo-Wellcome Research, UK. Dig Dis Sci 1997; 42: 223-41.
5. Camilleri M. Testing the sensitivity hypothesis in practice: tools and methods, assumptions and pitfalls. Gut 2002; 51 (Suppl. 1): i34-40.
6. Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut 1973; 14: 125-32.
7. Bouin M, Plourde V, Boivin M, et al. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 2002; 122: 1771-7.
8. Mearin F, Cucala M, Azpiroz F, et al. The origin of symptoms on the brain-gut axis in functional dyspepsia. Gastroenterology 1991; 101: 999-1006.
9. Tack J, Caenepeel P, Fischler B, et al. Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia. Gastroenterology 2001; 121: 526-35.
10. Chang L, Mayer EA, Johnson T, et al. Differences in somatic perception in female patients with irritable bowel syndrome with and without fibromyalgia. Pain 2000; 84: 297-307.
11. Cook IJ, van Eeden A, Collins SM. Patients with irritable bowel syndrome have greater pain tolerance than normal subjects. Gastroenterology 1987; 93: 727-33.
12. Camilleri M, Coulie B, Tack JF. Visceral hypersensitivity: facts, speculations, and challenges. Gut 2001; 48: 125-31.
13. Bueno L, Fioramonti J, Delvaux M, et al. Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. Gastroenterology 1997; 112: 1714-43.
14. Kirkup AJ, Brunsden AM, Grundy D. Receptors and transmission in the brain-gut axis: potential for novel therapies: I. Receptors on visceral afferents. Am J Physiol 2001; 280: G787-94.
15. Gebhart GF. Pathobiology of visceral pain: molecular mechanisms and therapeutic implications: IV. Visceral afferent contributions to the pathobiology of visceral pain. Am J Physiol 2000; 278: G834-8.
16. Kuiken SD, Lei A, Tytgat GN, et al. Effect of the low-affinity, noncompetitive N-methyl-d-aspartate receptor antagonist dextromethorphan on visceral perception in healthy volunteers. Aliment Pharmacol Ther 2002; 16: 1955-62.
17. Sarkar S, Hobson AR, Hughes A, et al. The prostaglandin E2 receptor-1 (EP-1) mediates acid-induced visceral pain hypersensitivity in humans. Gastroenterology 2003; 124: 18-25.
18. Sun WM, Edwards CA, Prior A, et al. Effect of oral nicardipine on anorectal function in normal human volunteers and patients with irritable bowel syndrome. Dig Dis Sci 1990; 35: 885-90.
19. Kuiken SD, Vergeer M, Heisterkamp SH, et al. Role of nitric oxide in gastric motor and sensory functions in healthy subjects. Gut 2002; 51: 212-8.
20. Haley J, Ketchum S, Dickenson A. Peripheral kappa-opioid modulation of the formalin response: an electrophysiological study in the rat. Eur J Pharmacol 1990; 191: 437-46.
21. Johnson SM, Duggan AW. Evidence that the opiate receptors of the substantia gelatinosa contribute to the depression, by intravenous morphine, of the spinal transmission of impulses in unmyelinated primary afferents. Brain Res 1981; 207: 223-8.
22. Ninkovic M, Hunt SP, Gleave JR. Localization of opiate and histamine H1-receptors in the primate sensory ganglia and spinal cord. Brain Res 1982; 241: 197-206.
23. Inturrisi CE. Clinical pharmacology of opioids for pain. Clin J Pain 2002; 18: S3-13.
24. Diop L, Riviere PJ, Pascaud X, et al. Peripheral kappa-opioid receptors mediate the antinociceptive effect of fedotozine (correction of fetodozine) on the duodenal pain reflex in rat. Eur J Pharmacol 1994; 271: 65-71.
25. Diop L, Riviere PJ, Pascaud X, et al. Role of vagal afferents in the antinociception produced by morphine and U-50,488H in the colonic pain reflex in rats. Eur J Pharmacol 1994; 257: 181-7.
26. Langlois A, Diop L, Riviere PJ, et al. Effect of fedotozine on the cardiovascular pain reflex induced by distension of the irritated colon in the anesthetized rat. Eur J Pharmacol 1994; 271: 245-51.
27. Sengupta JN, Snider A, Su X, et al. Effects of kappa opioids in the inflamed rat colon. Pain 1999; 79: 175-85.
28. Holzer P. Gastrointestinal afferents as targets of novel drugs for the treatment of functional bowel disorders and visceral pain. Eur J Pharmacol 2001; 429: 177-93.
29. Fioramonti J, Bueno L. Centrally acting agents and visceral sensitivity. Gut 2002; 51 (Suppl. 1): i91-5.
30. Lembo T, Naliboff BD, Matin K, et al. Irritable bowel syndrome patients show altered sensitivity to exogenous opioids. Pain 2000; 87: 137-47.
31. Coffin B, Bouhassira D, Chollet R, et al. Effect of the kappa agonist fedotozine on perception of gastric distension in healthy humans. Aliment Pharmacol Ther 1996; 10: 919-25.
32. Coffin B, Farmachidi JP, Rueegg P, et al. Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distension in healthy subjects. Aliment Pharmacol Ther 2003; 17: 577-85.
33. Delvaux M, Louvel D, Lagier E, et al. The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome. Gastroenterology 1999; 116: 38-45.
34. Bradette M, Delvaux M, Staumont G, et al. Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone. Dig Dis Sci 1994; 39: 1171-8.
35. Dapoigny M, Abitbol JL, Fraitag B. Efficacy of peripheral kappa agonist fedotozine versus placebo in treatment of irritable bowel syndrome. A multicenter dose-response study. Dig Dis Sci 1995; 40: 2244-9.
36. Fraitag B, Homerin M, Hecketsweiler P. Double-blind dose-response multicenter comparison of fedotozine and placebo in treatment of nonulcer dyspepsia. Dig Dis Sci 1994; 39: 1072-7.
37. Read NW, Abitbol JL, Bardhan KD, et al. Efficacy and safety of the peripheral kappa agonist fedotozine versus placebo in the treatment of functional dyspepsia. Gut 1997; 41: 664-8.
38. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001; 15: 355-61.
39. Delvaux M, Wingate D. Trimebutine: mechanism of action, effects on gastrointestinal function and clinical results. J Int Med Res 1997; 25: 225-46.
40. Efskind PS, Bernklev T, Vatn MH. A double-blind placebo-controlled trial with loperamide in irritable bowel syndrome. Scand J Gastroenterol 1996; 31: 463-8.
41. Cann PA, Read NW, Holdsworth CD, et al. Role of loperamide and placebo in management of irritable bowel syndrome (IBS). Dig Dis Sci 1984; 29: 239-47.
42. Lavo B, Stenstam M, Nielsen AL. Loperamide in treatment of irritable bowel syndrome - a double-blind placebo controlled study. Scand J Gastroenterol Suppl 1987; 130: 77-80.
43. DeHaven-Hudkins DL, Burgos LC, Cassel JA, et al. Loperamide (ADL 2-1294), an opioid antihyperalgesic agent with peripheral selectivity. J Pharmacol Exp Ther 1999; 289: 494-502.
44. Kim DY, Camilleri M. Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 2000; 95: 2698-709.
45. Grider JR. CGRP as a transmitter in the sensory pathway mediating peristaltic reflex. Am J Physiol 1994; 266: G1139-45.
46. Kozlowski CM, Green A, Grundy D, et al. The 5-HT(3) receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat. Gut 2000; 46: 474-80.
47. Hicks GA, Coldwell JR, Schindler M, et al. Excitation of rat colonic afferent fibres by 5-HT(3) receptors. J Physiol 2002; 544: 861-9.
48. Schikowski A, Thewissen M, Mathis C, et al. Serotonin type-4 receptors modulate the sensitivity of intramural mechanoreceptive afferents of the cat rectum. Neurogastroenterol Motil 2002; 14: 221-7.
49. Danzebrink RM, Gebhart GF. Evidence that spinal 5-HT1, 5-HT2 and 5-HT3 receptor subtypes modulate responses to noxious colorectal distension in the rat. Brain Res 1991; 538: 64-75.
50. Gershon MD. Review article: Roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 1999; 13 (Suppl. 2): 15-30.
51. Tack J, Coulie B, Wilmer A, et al. Influence of sumatriptan on gastric fundus tone and on the perception of gastric distension in man. Gut 2000; 46: 468-73.
52. Coulie B, Tack J, Janssens J. Influence of buspirone-induced fundus relaxation: on the perception of gastric distention in man [abstract]. Gastroenterology 1997; 112: A715.
53. Tack J, Coulie B, Degreef T, et al. Influence of sumatriptan on the perception of gastric distention in patients with functional dyspepsia [abstract]. Gastroenterology 1997; 112: A304.
54. Tack J, Piessevaux H, Coulie B, et al. A placebo-controlled trial of buspirone, a fundus-relaxing drug, in functional dyspepsia: effect on symptoms and gastric sensory and motor function [abstract]. Gastroenterology 1999; 116: A325.
55. Chial HJ, Camilleri M, Ferber I, et al. Effects of venlafaxine, buspirone, and placebo on colonic sensorimotor functions in healthy humans. Clin Gastroenterol Hepatol 2003; 1: 211-8.
56. Tack J, Piessevaux H, Coulie B, et al. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998; 115: 1346-52.
57. Boeckxstaens GE, Hirsch DP, Kuiken SD, et al. The proximal stomach and postprandial symptoms in functional dyspeptics. Am J Gastroenterol 2002; 97: 40-8.
58. Apter JT, Allen LA. Buspirone: future directions. J Clin Psychopharmacol 1999; 19: 86-93.
59. Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002; 122: 1140-56.
60. Zighelboim J, Talley NJ, Phillips SF, et al. Visceral perception in irritable bowel syndrome. Rectal and gastric responses to distension and serotonin type 3 antagonism. Dig Dis Sci 1995; 40: 819-27.
61. Goldberg PA, Kamm MA, Setti-Carraro P, et al. Modification of visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism (ondansetron). Digestion 1996; 57: 478-83.
62. Hammer J, Phillips SF, Talley NJ, et al. Effect of a 5HT3-antagonist (ondansetron) on rectal sensitivity and compliance in health and the irritable bowel syndrome. Aliment Pharmacol Ther 1993; 7: 543-51.
63. Zerbib F, Bruley des Varannes S, Oriola RC, et al. Alosetron does not affect the visceral perception of gastric distension in healthy subjects. Aliment Pharmacol Ther 1994; 8: 403-7.
64. Delvaux M, Louvel D, Mamet JP, et al. Effect of alosetron on responses to colonic distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1998; 12: 849-55.
65. Thumshirn M, Coulie B, Camilleri M, et al. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2000; 14: 869-78.
66. Klatt S, Bock W, Rentschler J, et al. Effects of tropisetron, a 5-HT3 receptor antagonist, on proximal gastric motor and sensory function in nonulcer dyspepsia. Digestion 1999; 60: 147-52.
67. Prior A, Read NW. Reduction of rectal sensitivity and postprandial motility by granisetron, a 5 HT3-receptor antagonist, in patients with irritable bowel syndrome. Aliment Pharmacol Ther 1993; 7: 175-80.
68. Simren M, Simms L, D'Souza D, et al. Lipid-induced colonic hypersensitivity in irritable bowel syndrome: the role of 5-HT3 receptors. Aliment Pharmacol Ther 2003; 17: 279-87.
69. Feinle C, Read NW. Ondansetron reduces nausea induced by gastroduodenal stimulation without changing gastric motility. Am J Physiol 1996; 271: G591-7.
70. Feinle C, Grundy D, Fried M. Modulation of gastric distension-induced sensations by small intestinal receptors. Am J Physiol 2001; 280: G51-7.
71. Mayer EA, Berman S, Derbyshire SW, et al. The effect of the 5-HT3 receptor antagonist, alosetron, on brain responses to visceral stimulation in irritable bowel syndrome patients. Aliment Pharmacol Ther 2002; 16: 1357-66.
72. Tecott LH, Maricq AV, Julius D. Nervous system distribution of the serotonin 5-HT3 receptor mRNA. Proc Natl Acad Sci U S A 1993; 90: 1430-4.
73. van Hooft JA, Vijverberg HP. 5-HT(3) receptors and neurotransmitter release in the CNS: a nerve ending story? Trends Neurosci 2000; 23: 605-10.
74. Camilleri M, Mayer EA, Drossman DA, et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999; 13: 1149-59.
75. Bardhan KD, Bodemar G, Geldof H, et al. A double-blind, randomized, placebo-controlled dose-ranging study to evaluate the efficacy of alosetron in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2000; 14: 23-34.
76. Camilleri M, Northcutt AR, Kong S, et al. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000; 355: 1035-40.
77. Camilleri M, Chey WY, Mayer EA, et al. A randomized controlled clinical trial of the serotonin type 3 receptor antagonist alosetron in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001; 161: 1733-40.
78. Lembo T, Wright RA, Bagby B, et al. Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001; 96: 2662-70.
79. Horton R. Lotronex and the FDA: a fatal erosion of integrity. Lancet 2001; 357: 1544-5.
80. Drossman DA, Camilleri M, Mayer EA, et al. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123: 2108-31.
81. Caras S, Krause G, Biesheuvel E, et al. Cilansetron shows efficacy in male and female non-constipated patients with irritable bowel syndrome in a United States study [abstract]. Gastroenterology 2001; 120: A217.
82. Talley NJ, van Zanten SV, Saez LR, et al. A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia. Aliment Pharmacol Ther 2001; 15: 525-37.
83. Tack J, Vos R, Janssens J, et al. Influence of tegaserod on proximal gastric sensory and motor function in man [abstract]. Gastroenterology 2002; 122: A453.
84. Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15: 1655-66.
85. Novick J, Miner P, Krause R, et al. A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2002; 16: 1877-88.
86. Kellow J, Lee OY, Chang FY, et al. An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome. Gut 2003; 52: 671-6.
87. Bouras EP, Camilleri M, Burton DD, et al. Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder. Gastroenterology 2001; 120: 354-60.
88. Tack J, Delia T, Ligozio G, et al. A phase II placebo controlled randomized trial with tegaserod (T) in functional dyspepsia (FD) patients with normal gastric emptying (NGE) [abstract]. Gastroenterology 2002; 122: A20.
89. O'Malley PG, Jackson JL, Santoro J, et al. Antidepressant therapy for unexplained symptoms and symptom syndromes. J Fam Pract 1999; 48: 980-90.
90. Coquoz D, Porchet HC, Dayer P. Central analgesic effects of desipramine, fluvoxamine, and moclobemide after single oral dosing: a study in healthy volunteers. Clin Pharmacol Ther 1993; 54: 339-44.
91. Gorelick AB, Koshy SS, Hooper FG, et al. Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans. Am J Physiol 1998; 275: G460-6.
92. Korzeniewska-Rybicka I, Plaznik A. Analgesic effect of antidepressant drugs. Pharmacol Biochem Behav 1998; 59: 331-8.
93. Singh VP, Jain NK, Kulkarni SK. On the antinociceptive effect of fluoxetine, a selective serotonin reuptake inhibitor. Brain Res 2001; 915: 218-26.
94. Peghini PL, Katz PO, Castell DO. Imipramine decreases oesophageal pain perception in human male volunteers. Gut 1998; 42: 807-13.
95. Mertz H, Fass R, Kodner A, et al. Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am J Gastroenterol 1998; 93: 160-5.
96. Poitras P, Riberdy PM, Plourde V, et al. Evolution of visceral sensitivity in patients with irritable bowel syndrome. Dig Dis Sci 2002; 47: 914-20.
97. Mertz H, Pickens D, Morgan V. Amitriptyline reduces activation of the anterior cingulate cortex in irritable bowel syndrome patients during rectal pain [abstract]. Gastroenterology 2003; 124: A370.
98. Jackson JL, O'Malley PG, Tomkins G, et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000; 108: 65-72.
99. Tanum L, Malt UF. A new pharmacologic treatment of functional gastrointestinal disorder. A double-blind placebo-controlled study with mianserin. Scand J Gastroenterol 1996; 31: 318-25.
100. Drossman DA, Toner BB, Whitehead WE, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003; 125: 19-31.
101. Tack J, Broekaert D, Coulie B, et al. Influence of the selective serotonin re-uptake inhibitor, paroxetine, on gastric sensorimotor function in humans. Aliment Pharmacol Ther 2003; 17: 603-8.
102. Kuiken SD, Tytgat GN, Boeckxstaens GE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo controlled study. Clin Gastroenterol Hepatol 2003; 1: 219-28.
103. Creed F, Fernandes L, Guthrie E, et al. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003; 124: 303-17.
104. Chrubasik J, Meynadier J, Scherpereel P, et al. The effect of epidural somatostatin on postoperative pain. Anesth Analg 1985; 64: 1085-8.
105. Penn RD, Paice JA, Kroin JS. Intrathecal octreotide for cancer pain. Lancet 1990; 335: 738.
106. Su X, Burton MB, Gebhart GF. Effects of octreotide on responses to colorectal distension in the rat. Gut 2001; 48: 676-82.
107. Schindler M, Humphrey PP, Emson PC. Somatostatin receptors in the central nervous system. Prog Neurobiol 1996; 50: 9-47.
108. Kaupmann K, Bruns C, Hoyer D, et al. Distribution and second messenger coupling of four somatostatin receptor subtypes expressed in brain. FEBS Lett 1993; 331: 53-9.
109. Senaris RM, Schindler M, Humphrey PP, et al. Expression of somatostatin receptor 3 mRNA in the motorneurones of the rat spinal cord, and the sensory neurones of the spinal ganglia. Brain Res Mol Brain Res 1995; 29: 185-90.
110. Hokfelt T, Elde R, Johansson O, et al. Immunohistochemical evidence for separate populations of somatostatin-containing and substance P-containing primary afferent neurons in the rat. Neuroscience 1976; 1: 131-6.
111. Banks WA, Schally AV, Barrera CM, et al. Permeability of the murine blood-brain barrier to some octapeptide analogs of somatostatin. Proc Natl Acad Sci U S A 1990; 87: 6762-6.
112. Befon S, Mystakidou K, Lyra M, et al. Continuous subcutaneous octreotide in gastrointestinal cancer patients: pain control and beta-endorphin levels. Anticancer Res 2000; 20: 4039-46.
113. Mayer EA. Some of the challenges in drug development for irritable bowel syndrome. Gut 2001; 48: 585-6.
114. Johnston BT, Shils J, Leite LP, et al. Effects of octreotide on esophageal visceral perception and cerebral evoked potentials induced by balloon distension. Am J Gastroenterol 1999; 94: 65-70.
115. Foxx-Orenstein A, Camilleri M, Stephens D, et al. Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans. Gut 2003; 52: 1555-61.
116. Mertz H, Walsh JH, Sytnik B, et al. The effect of octreotide on human gastric compliance and sensory perception. Neurogastroenterol Motil 1995; 7: 175-85.
117. Plourde V, Lembo T, Shui Z, et al. Effects of the somatostatin analogue octreotide on rectal afferent nerves in humans. Am J Physiol 1993; 265: G742-51.
118. Schwetz I, Naliboff B, Munakata J, et al. Anti-hyperalgesic effect of octreotide in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2004; 19: 123-31.
119. Hasler WL, Soudah HC, Owyang C. A somatostatin analogue inhibits afferent pathways mediating perception of rectal distention. Gastroenterology 1993; 104: 1390-7.
120. Chey WD, Beydoun A, Roberts DJ, et al. Octreotide reduces perception of rectal electrical stimulation by spinal afferent pathway inhibition. Am J Physiol 1995; 269: G821-6.
121. Talley NJ, Turner I, Middleton WR. Somatostatin and symptomatic relief of irritable bowel syndrome. Lancet 1987; 2: 1144.
122. Ducrotte P, Maillot C, Leroi AM, et al. Octreotide in refractory functional epigastric pain with nutritional impairment - an open study. Aliment Pharmacol Ther 1999; 13: 969-75.
123. Unnerstall JR, Kopajtic TA, Kuhar MJ. Distribution of alpha 2 agonist binding sites in the rat and human central nervous system: analysis of some functional, anatomic correlates of the pharmacologic effects of clonidine and related adrenergic agents. Brain Res 1984; 319: 69-101.
124. Takano Y, Takano M, Yaksh TL. The effect of intrathecally administered imiloxan and WB4101: possible role of alpha 2-adrenoceptor subtypes in the spinal cord. Eur J Pharmacol 1992; 219: 465-8.
125. Viramontes BE, Malcolm A, Camilleri M, et al. Effects of an alpha(2)-adrenergic agonist on gastrointestinal transit, colonic motility, and sensation in humans. Am J Physiol 2001; 281: G1468-76.
126. Bonnet F, Boico O, Rostaing S, et al. Clonidine-induced analgesia in postoperative patients: epidural versus intramuscular administration. Anesthesiology 1990; 72: 423-7.
127. Saeki S, Yaksh TL. Suppression by spinal alpha-2 agonists of motor and autonomic responses evoked by low- and high-intensity thermal stimuli. J Pharmacol Exp Ther 1992; 260: 795-802.
128. Thumshirn M, Camilleri M, Choi MG, et al. Modulation of gastric sensory and motor functions by nitrergic and alpha2-adrenergic agents in humans. Gastroenterology 1999; 116: 573-85.
129. Bharucha AE, Camilleri M, Zinsmeister AR, et al. Adrenergic modulation of human colonic motor and sensory function. Am J Physiol 1997; 273: G997-1006.
130. Camilleri M, Kim DY, McKinzie S, et al. A randomized, controlled exploratory study of clonidine in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2003; 1: 111-21.
131. Stanghellini V, De Ponti F, De Giorgio R, et al. New developments in the treatment of functional dyspepsia. Drugs 2003; 63: 869-92.
132. Mertz H, Naliboff B, Munakata J, et al. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995; 109: 40-52.
133. Mertz H. Review article: Visceral hypersensitivity. Aliment Pharmacol Ther 2003; 17: 623-33.
134. Mertz H. Role of the brain and sensory pathways in gastrointestinal sensory disorders in humans. Gut 2002; 51 (Suppl. 1): 129-33.
135. Hasler WL, Soudah HC, Owyang C. Somatostatin analog inhibits afferent response to rectal distention in diarrhea-predominant irritable bowel patients. J Pharmacol Exp Ther 1994; 268: 1206-11.